Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics, a clinical stage biotechnology company focused on fibrosis treatment, announced that President and CEO Bernard Coulie will present a company update at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 7:30 a.m. PT / 10:30 a.m. ET.

The venue is the Elizabethan Room D at The Westin St. Francis, San Francisco. Pliant's lead product, bexotegrast (PLN-74809), is undergoing Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received multiple designations from the FDA and European Medicines Agency.

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 41^st Annual J.P. Morgan Healthcare Conference.

41^st Annual J.P. Morgan Healthcare Conference (January 9-12, 2023)

Presentation Date/Time:	January 10, 2023, at 7:30 a.m. PT/ 10:30 a.m. ET
Venue:	Elizabethan Room D The Westin St. Francis San Francisco San Francisco, California

Interested parties can access the company presentation from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time it is made available.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast (PLN-74809) has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant is currently conducting Phase 2a trials of bexotegrast (PLN-74809) in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.PliantRx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When will Pliant Therapeutics present at the J.P. Morgan Healthcare Conference?

Pliant Therapeutics will present on January 10, 2023, at 7:30 a.m. PT / 10:30 a.m. ET.

Where is the J.P. Morgan Healthcare Conference being held?

The conference will take place at the Elizabethan Room D, The Westin St. Francis, San Francisco.

What is the focus of Pliant Therapeutics' presentation?

The presentation will provide a company update, including insights on their lead product candidate, bexotegrast (PLN-74809).

What is bexotegrast being developed for?

Bexotegrast is being developed for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

What designations has bexotegrast received?

Bexotegrast has received Fast Track and Orphan Drug Designations from the FDA and Orphan Drug Designation from the European Medicines Agency.